Abstracts Archive - Page 367 of 2425 - ACR Meeting Abstracts

Abstract Number: 054 • 2023 Pediatric Rheumatology Symposium
Craniofacial Localized Scleroderma: A Single Center Retrospective Cohort
Leigh Stubbs, Ammar Hashemi, Raegan Hunt and Renata Maricevich, Baylor College of Medicine, Houston, TX
Background/Purpose: Craniofacial localized scleroderma (LS) can lead to disfigurement and severe extracutaneous manifestations (ECMs). There is an ongoing need to standardize multidisciplinary evaluation and care.…
Abstract Number: 066 • 2023 Pediatric Rheumatology Symposium
Telemedicine Use in the Assessment of Juvenile Myositis: A Mixed-Methods Study of an International Healthcare Provider Experience
Y. Ingrid Goh¹, Peter Blier², Bianca Lang³, Marietta De Guzman⁴, Julie Fuller⁵, Kristin Houghton⁶, Kathryn Cook⁷, Susan Kim⁸, Vanessa Carbone¹, Heather Tory⁹, Jo-Anne Marcuz¹, Albert Chow¹⁰, Liza McCann¹¹, Charalampia Papadopoulou¹², Clarissa Pilkington¹³ and Stacey Tarvin¹⁴, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Retired, Amherst, MA, ³Dalhousie University - Halifax, Halifax, NS, Canada, ⁴Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁵UT Southwestern, Dallas, TX, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷Akron Children's Hospital, Akron, OH, ⁸UCSF Benioff Children's Hospital, San Francisco, CA, ⁹Connecticut Children's Medical Center, S Glastonbury, CT, ¹⁰Loma Linda University, Loma Linda, CA, ¹¹Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ¹²UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Section Head Infection, Immunology, and Rheumatology, London, United Kingdom, ¹³Great Ormond Street Hospital, London, United Kingdom, ¹⁴Riley Hospital for Children at Indiana University Health, Indianapolis, IN
Background/Purpose: Care of patients with juvenile myositis (JM) involves complex assessments performed by specialized healthcare providers (HCPs). Restrictions during the COVID-19 pandemic required the rapid…
Abstract Number: 093 • 2023 Pediatric Rheumatology Symposium
Comparison Between Induction with Rituximab and Cyclophosphamide in Treatment of Childhood-Onset ANCA-Associated Vasculitis
Samuel Gagne¹, Kimberly Morishita², Else Bosman³, Vidya Sivaraman⁴, David Cabral⁵, For the PedVas Investigators⁶ and Brett Klamer⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²University of British Columbia, Vancouver, BC, Canada, ³UBC, Vancouver, BC, Canada, ⁴Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ⁵BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁶PedVas, ⁷Biostatistics Resource at Nationwide Children’s Hospital (BRANCH), Nationwide Children’s Hospital, Columbus, OH
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are a group vasculitides with significant morbidity and mortality requiring toxic therapy. Clinical trials in adults…
Abstract Number: 083 • 2023 Pediatric Rheumatology Symposium
Running out of Rheum: Where Are the Pediatric Rheumatology Faculty?
McKenzie Vater¹, Miriah Gillispie-Taylor², Emma Austenfeld³ and Julia Shalen⁴, ¹Vanderbilt University Medical Center, Nashville, TN, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³MCWAH, Wauwatosa, WI, ⁴Johns Hopkins University, Baltimore, MD
Background/Purpose: The pediatric rheumatology workforce shortage has significant downstream effects on pediatric trainees and patients. Currently, 9 out of 50 states do not have a…
Abstract Number: 075 • 2023 Pediatric Rheumatology Symposium
Emapalumab Treatment Followed by Hematopoietic Stem Cell Transplantation in Systemic Juvenile Idiopathic Arthritis Complicated by Recurrent Macrophage Activation Syndrome
Claudia Bracaglia¹, Manuela Pardeo¹, Giulia Marucci², Simona Riccio², Francesco Quagliarella³, Ivan Caiello², Giusi Prencipe², Pietro Merli³, Franco Locatelli³ and Fabrizio De Benedetti¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Roma, Italy, ³Ospedale Pediatrico Bambino Gesù, Department of Hematology/Oncology, Cell and Gene Therapy, Roma, Italy
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening complication of different rheumatic diseases, particularly of systemic juvenile idiopathic arthritis (sJIA).Methods: We report the case of…
Abstract Number: 048 • 2023 Pediatric Rheumatology Symposium
Comparative Efficacy and Safety of Ibuprofen and Naproxen in the Treatment of Oligoarticular Juvenile Idiopathic Arthritis (oJIA): Bi-national Cohort Study
Orly Ohana¹, Itay Marmor², Liora Harel³, Shiri Rubin⁴, rotem tal⁵, Yoel Levinsky⁶, Orit Peled⁷ and Gil Amarilyo³, ¹Pediatric C ward, Schneider Children's Medical Centre, Petach Tikva, Israel, ²Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ³Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel, ⁴Pediatric Ear Nose and Throat Unit Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁵Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁶Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ⁷Department of Pharmacy, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
Background/Purpose: JIA is the most common childhood rheumatic disease. NSAIDs and intraarticular corticosteroid injections (IACI) are first-line therapy for oJIA. NSAIDs Adverse events (AEs) include…
Abstract Number: 085 • 2023 Pediatric Rheumatology Symposium
Identification of Barriers to Care Experienced by Children with Rheumatic Disease: A Qualitative Study
Olivia Kwan¹, Gloria Garcia², Kiana Johnson³, Melissa Oliver¹, Stacey Tarvin⁴, Alvaro Tori¹, Brandi Stevens¹ and Martha Rodriguez⁴, ¹Indiana University, Indianapolis, IN, ²Indiana University School of Medicine, Indianapolis, IN, ³East Tennessee State University, Johnson City, TN, ⁴Riley Hospital for Children at Indiana University Health, Indianapolis, IN
Background/Purpose: Pediatric rheumatic diseases are known to have disparities in disease outcomes, but many drivers of these inequities are unknown. Social determinants of health are…
Abstract Number: 095 • 2023 Pediatric Rheumatology Symposium
Systemic Juvenile Idiopathic Arthritis Associated Lung Disease in Europe
Claudia Bracaglia¹, Francesca Minoia², Christoph Kessel³, Sebastiaan Vastert⁴, Manuela Pardeo¹, Alessia Arduini¹, Sarka Fingerhutova⁵, Irina Nikishina⁶, Ozge Basaran⁷, Nural Kiper⁸, Mikhail Kostik⁹, Mia Glerup¹⁰, Roberta Caorsi¹¹, AnnaCarin Horne¹², Giovanni Filocamo², Helmut Wittkowski³, Marija Jelusic¹³, Jordi Anton¹⁴, Samira Khaldi-Plassart¹⁵, Alexandre Belot¹⁵, Gerd Horneff¹⁶, Seraina Palmer Sarrott¹⁷, Elvira Cannizzaro Schneider¹⁸, Lampros Fotis¹⁹, Pavla Dolezalova⁵, Angelo Ravelli²⁰, Seza Ozen⁷ and Fabrizio De Benedetti¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico, Milano, Italy, ³Department of Pediatric Rheumatology & Immunology, WWU Medical Center (UKM), Muenster, Germany, ⁴Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁵Centre for Paediatric Rheumatology and Autoinflammatory Diseases, Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, ⁶V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁷Department of Pediatrics, Division of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, ⁸Department of Pediatrics, Division of Pediatric Pulmonology, Hacettepe University, Ankara, Turkey, ⁹Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, ¹⁰Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ¹¹Department of Pediatrics and Rheumatology, IRRCS Istituto G. Gaslini, Genova, Italy, ¹²Department of pediatric rheumathology Karolinska University Hospital and Department of pediatrics, Karolinska Institute, Stockholm, Sweden, ¹³Department of Paediatrics, University of Zagreb School of Medicine, University Hospital Centre, Zagreb, Croatia, ¹⁴Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain, ¹⁵Pediatric Nephrology, Rheumatology, Dermatology Unit, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France, ¹⁶Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁷Paediatric Rheumatology University Children’s Hospital Zurich, Zurich, Zurich, Switzerland, ¹⁸Paediatric Rheumatology University Children’s Hospital Zurich, Zurich, Switzerland, ¹⁹Pediatric Rheumatology Division, 3rd Department of Pediatrics, National and Kapodistrian University of Athens,‘’ATTIKON’’ General University Hospital, Athens, Greece, ²⁰IRRCS Istituto Giannina Gaslini and Università degli Studi di Genova, Genova, Italy
Background/Purpose: Chronic parenchymal lung disease (LD) is a new emerging severe life-threatening complication of sJIA. The number of sJIA patients with LD is apparently increasing…
Abstract Number: 090 • 2023 Pediatric Rheumatology Symposium
Safety Outcomes of Combined Biologics Use in Pediatric Rheumatology: A Single Center Experience
Angela Chun¹, MaiLan Nguyen¹, Marietta De Guzman² and Andrea Ramirez³, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: The management of pediatric rheumatic disease has been forever changed by the advent of biologic drugs and the pursuit of targeted therapy. There is…
Abstract Number: 087 • 2023 Pediatric Rheumatology Symposium
Delays in Care, Declines in Health, and Food Insecurity in Pediatric Systemic Lupus Erythematosus Patients During the COVID-19 Pandemic
Rebecca Hetrick¹, Maria Pereira² and Marietta De Guzman³, ¹Indiana University School of Medicine, Indianapolis, IN, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: The COVID-19 pandemic created dramatic societal disruptions. Social distancing and measures to reduce disease spread rapidly reshaped healthcare delivery. Recognizing the burden of frequent…
Abstract Number: 098 • 2023 Pediatric Rheumatology Symposium
Characterization of Pulmonary Nodules in Juvenile-onset Systemic Sclerosis: A Single Center Case-Series
Jonathan Li¹, Franziska Rosser¹, Sameh Tadros¹ and Kathryn Torok², ¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Given the high prevalence of intestinal lung disease (ILD) in systemic sclerosis (SSc) and the low sensitivity of pulmonary function testing for diagnosing ILD,…
Abstract Number: 110 • 2023 Pediatric Rheumatology Symposium
Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases
Janna Shapiro¹, Florence Choi², Amy Xu³, Trang Duong⁴, Tania Watts¹, Anne-Claude Gingras⁵, Sasha Bernatsky⁶, Susanne Benseler⁷ and Rae Yeung⁸, ¹Department of Immunology, University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁴Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁵Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health; Department of Molecular Genetics, University of Toronto, Toronto, ON, ⁶Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montreal, Québec, Canada; Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁷Division of Rheumatology, Department of Paediatrics, The Alberta Children’s Hospital, Calgary, AB, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare antibody responses to COVID-19 vaccines among children with autoimmune diseases taking different classes of immunosuppressantsMethods: A prospective observational study was conducted at…
Abstract Number: 111 • 2023 Pediatric Rheumatology Symposium
Monitoring for Hypogammaglobulinemia After B-Cell Therapy in an Academic Pediatric Center
Omar Mostafa, Sharon Bout-Tabaku, Buthaina Al-Adba, Ahmad Kaddourah, Abubakr Imam, Ibrahim Shatat and Mohammed Yousuf Karim, Sidra Medicine, Ar-Rayyan, Qatar
Background/Purpose: Hypogammaglobulinemia is an under-recognized complication of B-cell targeted therapies (BCTT) in both autoimmune diseases (AID) and malignancy. Hypogammaglobulinemia may be transient or persistent, and…
Abstract Number: 104 • 2023 Pediatric Rheumatology Symposium
Prevalence of Celiac Disease Among Children and Adolescents with Systemic Lupus Erythematosus (SLE)
Oscar Mwizerwa¹, Andrea Knight², Daniela Dominguez², Deborah Levy², Holly Convery², Kendal Thompson², Nicholas Gold², Catharine Walsh² and Linda Hiraki², ¹University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) and celiac disease (CD) are autoimmune diseases characterized by the presence of specific autoantibodies. We aimed to investigate the prevalence…
Abstract Number: 069 • 2023 Pediatric Rheumatology Symposium
Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios of Patients with Juvenile Systemic Lupus Erythematosus
Rogerio do Prado¹, Fabiola I Suano-Souza¹, Wellington D. R. Rodrigues², Lucila Pereira¹, Maria Teresa Terreri³ and Roseli O. S. Sarni⁴, ¹FMABC, São Paulo, Brazil, ²Unicid, São Paulo, Brazil, ³UNIFESP, São Paulo, Brazil, ⁴Centro Universitário Faculdade de Medicina do ABC (FMABC), Brazil
Background/Purpose: The Neutrophil-Lymphocyte ratio (NLR) and Platelet-Lymphocyte ratio (PLR) are markers of systemic inflammation easily available from the blood count. Previous studies have revealed that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].